Remdesivir shows promise in severe COVID-19 patients

NCT ID NCT04365725

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 84 hospitalized adults with severe COVID-19 who received the drug remdesivir. Researchers analyzed their recovery over 15 days to see how the drug affected their clinical course. The goal was to understand if remdesivir helps improve outcomes in severe cases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

remdesivir

What this could lead to

If successful, this could confirm remdesivir as a treatment to help hospitalized COVID-19 patients recover faster.

What could go wrong

This is a small, retrospective study without a control group, so results may not be definitive. Remdesivir has shown mixed results in other trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Cochin

    Paris, 75014, France